Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on July 15, 2025
MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy
GlobeNewswire
·
July 15, 2025
NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies, today announced the publication of a peer-reviewed …
IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan
GlobeNewswire
·
July 15, 2025
Management provides Nasdaq Hearing Panel with a comprehensive executable plan for long term compliance LAWRENCEVILLE, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated …
Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled
GlobeNewswire
·
July 15, 2025
Vancouver, Canada, July 15, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
GlobeNewswire
·
July 15, 2025
BERKELEY, Calif. and MAINZ, Germany, July 15, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major …
Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
GlobeNewswire
·
July 15, 2025
TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway …
Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025
GlobeNewswire
·
July 15, 2025
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the …
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
GlobeNewswire
·
July 15, 2025
Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extension This patent covers novel cyclic peptides and their use in treating solid tumors BASKING RIDGE, N.J, July 15, 2025 (GLOBE NEWSWIRE) -- …
OncoC4 to Present at the 2025 Orphan Drug Summit on Strategies to Eliminate Anti-Drug Antibodies in Orphan Therapies
GlobeNewswire
·
July 15, 2025
ROCKVILLE, Md., July 15, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, today announced it will present at the upcoming 2025 Orphan Drug Summit being held July 16-27, 2025, in Boston, …
Florida Oncology and Hematology Expands Fort Myers Clinic, Adds PET Services
GlobeNewswire
·
July 15, 2025
FORT MYERS, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Florida Oncology and Hematology, a partner practice of American Oncology Network (AON), has expanded its Fort Myers clinic at 14551 Hope Center Loop to include radiology services. Current and prospective …
Extendicare Announces July 2025 Dividend of C$0.042 per Share
GlobeNewswire
·
July 15, 2025
MARKHAM, Ontario, July 15, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of July 2025, which is payable on …
HealthLynked Engages Meridian Group to Accelerate Strategic Partnerships and Revenue Growth
GlobeNewswire
·
July 15, 2025
NAPLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- via IBN – HealthLynked Corp. (OTCQB: HLYK), a leader in healthcare technology and patient engagement solutions, today announced that it has engaged Meridian Group, a premier strategic advisory firm, to assist …
Medera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial for Duchenne Muscular Dystrophy Associated Cardiomyopathy
GlobeNewswire
·
July 15, 2025
BOSTON and KANSAS CITY, Kan., July 15, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, and its clinical development …
Auerbach Hematology and Oncology Joins American Oncology Network, Becomes The Center for Cancer and Blood Disorders – Baltimore
GlobeNewswire
·
July 15, 2025
BALTIMORE, July 15, 2025 (GLOBE NEWSWIRE) -- Auerbach Hematology and Oncology Associates PC, a trusted name in hematology and oncology care in Baltimore, Maryland, is proud to announce it has joined American Oncology Network (AON), one of the nation’s …
Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01
GlobeNewswire
·
July 15, 2025
Dr. Lotan’s distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada’s NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- …
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
GlobeNewswire
·
July 15, 2025
PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of weekly injections. The GLP-1 delivery platform expands …
Polyrizon Retains Nasdaq Listing Following Hearings Panel
GlobeNewswire
·
July 15, 2025
Raanana, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it has received a …
SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study
GlobeNewswire
·
July 15, 2025
The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg Twice a Week (BIW) and 50% in AML MR with …
Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
GlobeNewswire
·
July 15, 2025
– Mean weight loss of 19.2% at 6 mg with no plateau in 48-week Phase 3 trial – – Favorable safety profile consistent with other GLP-1-based treatments – – Hengrui to submit NDA in China; Kailera plans to evaluate both higher doses and longer duration of …
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
GlobeNewswire
·
July 15, 2025
SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for …
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
GlobeNewswire
·
July 15, 2025
GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2025. Participants can …